TargImmune Therapeutics is focused on drug development using novel targeted onco-immunotherapies.
TargImmune Therapeutics has raised $19.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in July 2021.
TargImmune Therapeutics's investors include EISMEA.
TargImmune Therapeutics is headquartered in Basel, Switzerland.
TargImmune Therapeutics is focused on drug development using novel targeted onco-immunotherapies.
TargImmune Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TargImmune Therapeutics — Funding & Investors." VCBacked, July 19, 2021, https://www.vcbacked.co/company/targimmune-therapeutics. Accessed November 13, 2026.
VCBacked. (2021). TargImmune Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/targimmune-therapeutics
{{cite web |title=TargImmune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/targimmune-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at TargImmune Therapeutics? Request a listing update